Janus Henderson Group PLC C4 Therapeutics, Inc. Transaction History

Janus Henderson Group PLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.1 - $9.02 $2.26 Million - $6.56 Million	-727,548 Reduced 98.5%	11,081 $34,000
Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $434,239 - $820,408	-80,118 Reduced 9.79%	738,629 $4.36 Million
Q3 2022 Nov 14, 2022	SELL	$8.03 - $12.77 $247,749 - $393,992	-30,853 Reduced 3.63%	818,747 $7.18 Million
Q2 2022 Aug 15, 2022	SELL	$5.06 - $26.46 $1.2 Million - $6.28 Million	-237,182 Reduced 21.82%	849,600 $6.41 Million
Q1 2022 May 16, 2022	BUY	$19.99 - $33.23 $816,331 - $1.36 Million	40,837 Added 3.9%	1,086,782 $26.4 Million
Q4 2021 Feb 14, 2022	SELL	$29.39 - $46.86 $86,494 - $137,908	-2,943 Reduced 0.28%	1,045,945 $33.7 Million
Q3 2021 Nov 16, 2021	SELL	$35.91 - $50.5 $3.03 Million - $4.25 Million	-84,241 Reduced 7.43%	1,048,888 $46.9 Million
Q2 2021 Aug 16, 2021	SELL	$30.39 - $42.18 $4.94 Million - $6.85 Million	-162,461 Reduced 12.54%	1,133,129 $42.9 Million
Q1 2021 May 17, 2021	SELL	$31.96 - $46.5 $64,527 - $93,883	-2,019 Reduced 0.16%	1,295,590 $46.5 Million
Q4 2020 Feb 16, 2021	BUY	$22.8 - $37.05 $29.6 Million - $48.1 Million	1,297,609 New	1,297,609 $40.4 Million

129

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $164M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.